ViiV Healthcare has granted a voluntary license to the Medicines Patent Pool (MPP) for pediatric formulations of the antiretroviral drug abacavir in 118 countries, according to a ViiV statement. The World Health Organization (WHO) currently recommends abacavir as a preferred nucleoside reverse transcriptase inhibitor (NRTI) for first-line therapy in infants and children. Founded in 2010, MPP is a United Nations–backed group that aims to lower HIV drug prices.

To read the statement, click here.